Wednesday, July 30, 2025

Amarin Corporation plc (NASDAQ:AMRN) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ETCompany ParticipantsAaron D.

Friday, July 18, 2025

MAMA, BSET, and AMRN are breakout stocks to watch, each boasting double-digit earnings growth potential in 2025.

Thursday, July 17, 2025

MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.

Monday, July 14, 2025

European equities traded in the US as American depositary receipts edged up Monday with the S&P Euro

Monday, July 14, 2025

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Thursday, July 10, 2025

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Thursday, July 10, 2025

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Wednesday, July 9, 2025

Shares of ProKidney jump 515% after its kidney cell therapy shows strong efficacy in a Phase II diabetes-related CKD study.

Thursday, July 3, 2025

Amarin Corporation plc announced as previously reported in the Original 8-K, the board appointed Michael Torok as a new non-employee director of the company, effective on April 4, 2025. The board...

Tuesday, July 1, 2025

European equities traded in the US as American depositary receipts edged higher late Tuesday morning

Monday, June 30, 2025

European equities traded in the US as American depositary receipts were modestly higher late Thursda

Friday, June 27, 2025

European equities traded in the US as American depositary receipts were tracking higher late Friday

Wednesday, June 25, 2025

AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.

Wednesday, June 25, 2025

European equities traded in the US as American depositary receipts were tracking lower late Wednesda

Wednesday, June 25, 2025

Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.

Wednesday, June 25, 2025

Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Tuesday, June 24, 2025

Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index adding 1.3% and the

Tuesday, June 24, 2025

Health care stocks rose Tuesday afternoon with the NYSE Health Care Index adding 0.7% and the Health

Tuesday, June 24, 2025

European equities traded in the US as American depositary receipts were higher late Tuesday morning,

Tuesday, June 24, 2025

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE Vazkepa® supported by strong clinical data package and expected to contribute to Specialty &

Tuesday, June 24, 2025

-- Company to Streamline Global Operations, Resulting in Approximately $70 Million of Cost Savings Over Next 12 Months and Accelerated Path to Positive Cash Flow -- -- Conference Call Today at 8:00 a.

Tuesday, June 24, 2025

Presentation Operator MessageOperator Welcome to Amarin Corporation's conference call. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and...

Tuesday, June 24, 2025

AMARIN'S REFINED STRATEGY INVESTOR PRESENTATION JUNE 24, 2025 ...

Thursday, June 19, 2025

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Monday, June 16, 2025

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Monday, June 16, 2025

Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.

Tuesday, June 10, 2025

Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tuesday, June 10, 2025

AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.

Friday, June 6, 2025

Amarin faces revenue declines due to generic competition, with losses outpacing revenue. Explore challenges, risks, and M&A potential. Learn more on AMRN stock here.

Thursday, May 29, 2025

Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.

Saturday, May 10, 2025

It's shaping up to be a tough period for Amarin Corporation plc ( NASDAQ:AMRN ), which a week ago released some...

Thursday, May 8, 2025

AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.

Thursday, May 8, 2025

Amarin ( NASDAQ:AMRN ) First Quarter 2025 Results Key Financial Results Revenue: US$42.0m (down 26% from 1Q 2024). Net...

Thursday, May 8, 2025

Amarin Corp PLC (AMRN) extends its European IP protection and expands VESCEPA's global reach, while navigating revenue declines due to generic competition.

Wednesday, May 7, 2025

DUBLIN (AP) — Amarin Corp. PLC (AMRN) on Wednesday reported a loss of $15.7 million in its first quarter. The Dublin-based company said it had a loss of 4 cents per share.

Wednesday, May 7, 2025

Amarin Corporation plc (NASDAQ:AMRN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ETCompany ParticipantsMark Marmur - Vice President of Corporate...

Wednesday, May 7, 2025

-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global V

Wednesday, May 7, 2025

The following slide deck was published by Amarin Corporation plc in conjunction with their 2025 Q1 earnings call.

Wednesday, May 7, 2025

First Quarter 2025 Financial Results & Business Update Conference Call May 7, 2025 ...

Wednesday, May 7, 2025

Amarin Corporation plc reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported revenue was USD 42.02 million compared to USD 56.52 million a..

Saturday, May 3, 2025

Standex International Corp (SXI) reports record adjusted margins and robust growth in key segments, despite facing tariff impacts and cash flow challenges.

Tuesday, April 29, 2025

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company’s Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA – DUBLIN and BRIDGEWATER, N.J., April 29

Monday, April 28, 2025

DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members

Monday, April 28, 2025

Presentation Operator MessageOperator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference

Wednesday, April 9, 2025

Action Taken to Maintain Company’s Nasdaq ListingDUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today confirmed that April 11, 2025 will be the

Monday, April 7, 2025

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of inv

Monday, March 31, 2025

– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important Pati

Wednesday, March 19, 2025

Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index down 0.1% an

Wednesday, March 19, 2025

AMARIN SHAREHOLDERS RADOFF ANDTOROK: * AMARIN SHAREHOLDERS RADOFF AND TOROK: AMARIN BOARD SHOULDIMMEDIATELY ANNOUNCE, RUN STRATEGIC REVIEW MAXIMIZING VALUE FORALL SHAREHOLDERSSource...

Wednesday, March 19, 2025

DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional in vitro mechanistic data with eicosapentaenoic acid (EPA) will be

Thursday, March 13, 2025

Amarin incurs a wider-than-expected loss in Q4. Revenues beat estimates. It plans to initiate a ratio change on its American Depositary Shares. Stock falls.

Thursday, March 13, 2025

Amarin Corp PLC (AMRN) reports strong international growth and strategic advancements despite US market pressures.

Wednesday, March 12, 2025

AMRN earnings call for the period ending December 31, 2024.

Wednesday, March 12, 2025

On a per-share basis, the Dublin-based company said it had a loss of 12 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research

Wednesday, March 12, 2025

1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq ListingDUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporat

Wednesday, March 12, 2025

-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- -- Fourth Quarter and Full-Year 2024 Pe

Wednesday, March 12, 2025

Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Conference Call March 12, 2025 8:00 AM ETCompany ParticipantsMark Marmur - Vice President of Corporate...

Thursday, February 27, 2025

-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with Ver

Tuesday, February 25, 2025

-- Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients -- -- Effective 1 April 2025, Austrian Reimbur

Tuesday, February 25, 2025

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Wednesday, February 19, 2025

DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members o

Wednesday, December 18, 2024

AMARIN APPOINTS PETER FISHMAN CHIEF FINANCIAL OFFICER -- Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the Company -- ...

Monday, December 16, 2024

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 -- -- Italy is the Third EU5 Market to Grant N

Friday, December 13, 2024

Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the CompanyDUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA

Tuesday, November 19, 2024

Amarin (AMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co

Tuesday, November 12, 2024

DUBLIN, BRIDGEWATER - Amarin Corporation plc today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without...

Monday, November 11, 2024

DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark R

Friday, November 1, 2024

Amarin Corp PLC (AMRN) faces revenue challenges in the U.S. while expanding its global footprint and maintaining a strong cash position.

Thursday, October 31, 2024

AMRN's third-quarter 2024 earnings meet estimates while revenues miss the same. Vascepa's sales in the United States decline year over year. Stock falls.

Thursday, October 31, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 31, 2024

AMRN earnings call for the period ending September 30, 2024.

Wednesday, October 30, 2024

DUBLIN (AP) — Amarin Corp. PLC (AMRN) on Wednesday reported a loss of $25.1 million in its third quarter. The Dublin-based company said it had a loss of 6 cents per share.

Wednesday, October 30, 2024

Amarin Corporation plc (NASDAQ:AMRN) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ETCompany ParticipantsMark Marmur - Vice President of...

Wednesday, October 30, 2024

-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW Partne

Wednesday, October 30, 2024

The following slide deck was published by Amarin Corporation plc in conjunction with their 2024 Q3 earnings call.

Wednesday, October 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 30, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 29, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 29, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 23, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 9, 2024

Amarin Corp PLC (AMRN) reports a decline in US revenues but sees growth potential in Europe and China amidst strategic cost reductions and regulatory advancements.

Tuesday, October 8, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 1, 2024

-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. 01, 2024

Friday, September 20, 2024

The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Read more here.

Thursday, September 19, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, September 18, 2024

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Tuesday, September 17, 2024

Aura Biosciences' strong data, focus on an unmet medical need, and solid execution make it a compelling biotech investment. Learn more about AURA stock here.